טוען...
Safety and Efficacy of Rivastigmine in Adolescents with Down Syndrome: A Preliminary 20-Week, Open-Label Study
Individuals with Down syndrome (DS) exhibit a cholinergic deficiency similar to that found in Alzheimer’s disease. Cholinesterase inhibitors, used to treat Alzheimer’s disease, may improve cognitive function in individuals with DS. This is the first investigation of the safety and efficacy of rivast...
שמור ב:
| Main Authors: | , , , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2006
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3129997/ https://ncbi.nlm.nih.gov/pubmed/17201619 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/cap.2006.16.755 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|